BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• 

  Drug Development

  Small Centessa Trial Shows Breakthrough Proof of Concept in Rare Disease

  Centessa showed positive early results from its Phase I Part B study on a potential drug that could direct mutation activity in patients with a particular gene that can cause liver and lung diseases.

  November 2, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Business

  Novartis Links with UK’s Dunad in $1.3 Billion Protein Degradation Deal

  Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.

  November 2, 2021

   · 

  2 min read

   · 

  Alex Keown
• 

  Business

  Moderna Moves Into Gene Editing Space with Metagenomi R&D Collab

  The partnership will leverage Metagenomi’s novel gene editing technology and Moderna’s mRNA platform, in addition to its lipid nanoparticle delivery technologies.

  November 2, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Business

  Merck’s Molnupiravir: When a Private-Public Partnership Bears Fruit

  In November 2019, Emory realized this experimental drug could have significant potential in respiratory viruses such as COVID-19.

  November 2, 2021

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Drug Development

  PDUFA Date Extended for Legend/Janssen Multiple Myeloma Drug

  The drug makers have until February 28, 2022 to review their findings and analytical processes for the drug they are developing to treat relapsed and/or refractory multiple myeloma.

  November 2, 2021

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Pharm Country

  Pfizer Q3: 2021 Guidance Raised to $81 Billion+, Strong Vaccine Sales and Gene Therapy Delays

  Pfizer reported its third-quarter 2021 financials, citing $24.1 billion in quarterly revenues, a stunning 130% operational growth.

  November 2, 2021

   · 

  3 min read

   · 

  Mark Terry
• 

  Drug Development

  COVID Update: CDC Meets on Pfizer-BioNTech Vaccine for Kids and Mandates Imminent

  The Centers for Disease Control and Prevention’s vaccine advisory committee meets today to discuss authorizing the Pfizer-BioNTech vaccine in children aged 5 to 11 years.

  November 2, 2021

   · 

  6 min read

   · 

  Mark Terry
• 

  Drug Development

  Trial Results from Clene Nanomedicine Strike ALS Research

  An announcement lit up the global grapevine today as Clene Nanomedicine released the results from Phase II of their RESCUE-ALS clinical trial.

  November 2, 2021

   · 

  2 min read

   · 

  Kaylei Whalen
• 

  Deals

  First Day Trading a Letdown for LianBio in Shadow of Beijing Market Crackdown

  Monday was a big day for LianBio, as the Shanghai-based company launched on the Nasdaq with an impressive $325 million initial public offering (IPO).

  November 2, 2021

   · 

  2 min read

   · 

  Heather McKenzie
• 

  Business

  Augmented Reality Test Diagnoses and Tracks Alzheimer’s for Early Intervention

  This novel diagnostic technology uses augmented reality and a smartphone or tablet to administer cognitive and functional tests.

  November 2, 2021

   · 

  5 min read

   · 

  Gail Dutton